AMRN stock news

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the… Read more

Amarin's stock jumped after SVB Leerink upped its rating on the biotech's stock to outperform, saying a recent double-digit decline offers a buying opportunity….AMRN Read more

Shares of the mid-cap biotech Amarin Corporation plc (NASDAQ: AMRN) were pulling back to their lowest level since early January on Friday. What … Read more

Amarin beats estimates for both earnings and revenues in the second quarter of 2019. Shares up. Read more

Biotech Amarin (AMRN) is one of Wall Street’s biggest standouts, with shares skyrocketing 566% in just the last year. Its fish-oil derivative drug Vascepa is already clinically proven to lower very high triglycerides without raising bad cholesterol. What’s more, recent trials revealed it could also cut Read more

Amarin announces strong preliminary sales of Vascepa in the second quarter. The company increases sales guidance for 2019. Read more

Amarin surges after the pharmaceutical company boosts its revenue guidance amid strong demand for its Vascepa chronic cardiovascular treatment….AMRN Read more

Shares of Amarin Corp. surged 9.2% in premarket trading Tuesday, after the pharmaceutical company raised its full-year revenue outlook and announced plans to… Read more

Amarin is preparing for a monumental label expansion for their flagship product Vascepa with a PDUFA date in September. I have been waiting patiently for an opp Read more

Amarin's (AMRN) label expansion application for hypertriglyceridemia drug, Vascepa, gets priority review from the FDA. Read more

The FDA plans to review Vascep within six months instead of the usual 10, with a decision on approval expected sometime in late September. Read more

"Halftime Report" traders Jon and Pete Najarian spot unusual options activity in shares of TJX, Amarin, and Oil Services ETF (OIH). Read more

Read more

Read more

Read more